Literature DB >> 21496129

Pyridoxine-dependent epilepsy: an under-recognised cause of intractable seizures.

Nune S Yeghiazaryan1, Federico Zara, Giuseppe Capovilla, Giorgia Brigati, Raffaele Falsaperla, Pasquale Striano.   

Abstract

Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder causing intractable seizures in neonates and infants. PDE patients are typically resistant to anti-epileptic treatment but respond to the administration of pyridoxine. Different seizure types have been reported in PDE, and episodes of status epilepticus are common. Electroencephalographic or neuroimaging abnormalities are not pathognomonic for this disorder. Intellectual disability is frequent at the follow-up. Recently, elevated urinary α-aminoadipic semialdehyde has been shown to be a reliable biomarker of this disorder, and mutations in the ALDH7A1 gene, encoding α-aminoadipic semialdehyde dehydrogenase, have been demonstrated in the large majority of PDE patients. However, early consideration of a pyridoxine trial remains the most important issue in a neonate or in an infant with intractable early onset seizures.
© 2010 The Authors. Journal of Paediatrics and Child Health © 2010 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21496129     DOI: 10.1111/j.1440-1754.2010.01866.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  14 in total

Review 1.  From Genetic Testing to Precision Medicine in Epilepsy.

Authors:  Pasquale Striano; Berge A Minassian
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

2.  Pyridoxine-dependent epilepsies: an observational study on clinical, diagnostic, therapeutic and prognostic features in a pediatric cohort.

Authors:  Raffaele Falsaperla; Maria Stella Vari; Irene Toldo; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Agnese Suppiej; Alberto Burlina; Mario Mastrangelo; Vincenzo Leuzzi; Valentina Marchiani; Paola De Liso; Giuseppe Capovilla; Pasquale Striano; Giovanna Vitaliti
Journal:  Metab Brain Dis       Date:  2017-11-25       Impact factor: 3.584

3.  Management of pediatric status epilepticus.

Authors:  Nicholas S Abend; Tobias Loddenkemper
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

4.  [Thiamine, pyridoxine and cobalamine. From myths to pharmacology and clinical practice].

Authors:  S Jesse; A C Ludolph
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

5.  Refractory Seizures Secondary to Vitamin B6 Deficiency in Parkinson Disease: The Role of Carbidopa-Levodopa.

Authors:  Adina Wise; Hernan Nicolas Lemus; Madeline Fields; Matthew Swan; Susan Bressman
Journal:  Case Rep Neurol       Date:  2022-06-27

Review 6.  Status epilepticus and refractory status epilepticus management.

Authors:  Nicholas S Abend; David Bearden; Ingo Helbig; Jennifer McGuire; Sona Narula; Jessica A Panzer; Alexis Topjian; Dennis J Dlugos
Journal:  Semin Pediatr Neurol       Date:  2014-12-12       Impact factor: 3.042

7.  Seizures Related to Vitamin B6 Deficiency in Adults.

Authors:  Dong-Gun Lee; Yeonkyung Lee; Hyeeun Shin; Kyusik Kang; Jong-Moo Park; Byung-Kun Kim; Ohyun Kwon; Jung-Ju Lee
Journal:  J Epilepsy Res       Date:  2015-06-30

8.  Pyridoxine dependent epilepsies: new therapeutical point of view.

Authors:  Raffaele Falsaperla; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2017-08-05       Impact factor: 2.638

Review 9.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Clinical and genetic characteristics of pyridoxine-dependent epilepsy: Case series report of three Chinese patients with phenotypic variability.

Authors:  Sanmei Wang; Jing Sun; Yao Tu; Lina Zhu; Zhichun Feng
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.